MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition

Journal of Pharmacology and Experimental Therapeutics

Volumn 355, Issue 3, 2015, Pages 397-409

  Fell, Matthew J ^a   Mirescu, Christian ^a   Basu, Kallol ^a   Cheewatrakoolpong, Boonlert ^a   DeMong, Duane E ^a   Ellis, J Michael ^a   Hyde, Lynn A ^a   Lin, Yinghui ^a   Markgraf, Carrie G ^a   Mei, Hong ^a   Miller, Michael ^a   Poulet, Frederique M ^a   Scott, Jack D ^a   Smith, Michelle D ^a   Yin, Zhizhang ^a   Zhou, Xiaoping ^a   Parker, Eric M ^a   Kennedy, Matthew E ^a   Morrow, John A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,6 DIMETHYL 4 (6 (5 (1 METHYLCYCLOPROPOXY) 1H INDAZOL 3 YL)PYRIMIDIN 4 YL)MORPHOLINE; LEUCINE RICH REPEAT KINASE 2; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG; 2,6-DIMETHYL-4-(6-(5-(1-METHYLCYCLOPROPOXY)-1H-INDAZOL-3-YL)PYRIMIDIN-4-YL)MORPHOLINE; ANTIPARKINSON AGENT; INDAZOLE DERIVATIVE; LRRK2 PROTEIN, MOUSE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ASSAY; COMPETITIVE BINDING ASSAY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EXPOSURE; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERANCE; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG ALVEOLUS CELL; LUNG STRUCTURE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; RADIOASSAY; TREATMENT DURATION; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; BINDING COMPETITION; BRAIN; BRAIN CHEMISTRY; BRAIN CORTEX; C57BL MOUSE; CELL LINE; DRUG EFFECTS; GENETICS; LUNG; METABOLISM; MUTATION; PARKINSON DISEASE; PATHOLOGY; PHOSPHORYLATION; PSYCHOLOGY;

ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; BINDING, COMPETITIVE; BRAIN; BRAIN CHEMISTRY; CELL LINE; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INDAZOLES; LUNG; MALE; MICE; MICE, INBRED C57BL; MUTATION; PARKINSON DISEASE; PHOSPHORYLATION; PNEUMOCYTES; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRIMIDINES;

EID: 84957419608     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.115.227587     Document Type: Article

References (32)

1. Baptista MA, Dave KD, Frasier MA, Sherer TB, Greeley M, Beck MJ, Varsho JS, Parker GA, Moore C, and Churchill MJ, et al. (2013) Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs. PLoS One 8:e80705.
2. Biskup S, Moore DJ, Celsi F, Higashi S, West AB, Andrabi SA, Kurkinen K, Yu SW, Savitt JM, and Waldvogel HJ, et al. (2006) Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol 60:557-569.
3. Bonifati V (2007) LRRK2 low-penetrance mutations (Gly2019Ser) and risk alleles (Gly2385Arg)-linking familial and sporadic Parkinson's disease. Neurochem Res 32:1700-1708.
4. Choi HG, Zhang J, Deng X, Hatcher JM, Patricelli MP, Zhao Z, Alessi DR, and Gray NS (2012) Brain Penetrant LRRK2 Inhibitor. ACS Med Chem Lett 3:658-662.
5. Cookson MR (2010) The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci 11:791-797.
6. Cooper O, Seo H, Andrabi S, Guardia-Laguarta C, Graziotto J, Sundberg M, McLean JR, Carrillo-Reid L, Xie Z, and Osborn T, et al. (2012) Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci Transl Med 4:141ra90.
7. Daher JP, Abdelmotilib HA, Hu X, Volpicelli-Daley LA, Moehle MS, Fraser KB, Needle E, Chen Y, Steyn SJ, Galatsis P, Hirst WD and West AB (2015) LRRK2 Pharmacological Inhibition Abates alpha-Synuclein Induced Neurodegeneration. J Biol Chem.
8. Deng X, Dzamko N, Prescott A, Davies P, Liu Q, Yang Q, Lee JD, Patricelli MP, Nomanbhoy TK, and Alessi DR, et al. (2011) Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat Chem Biol 7: 203-205.
9. Dzamko N, Deak M, Hentati F, Reith AD, Prescott AR, Alessi DR, and Nichols RJ (2010) Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J 430:405-413.
10. Ekstrand MI, Terzioglu M, Galter D, Zhu S, Hofstetter C, Lindqvist E, Thams S, Bergstrand A, Hansson FS, and Trifunovic A, et al. (2007) Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc Natl Acad Sci USA 104:1325-1330.
11. Estrada AA, Liu X, Baker-Glenn C, Beresford A, Burdick DJ, Chambers M, Chan BK, Chen H, Ding X, and DiPasquale AG, et al. (2012) Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J Med Chem 55:9416-9433.
12. Fuji RN, Flagella M, Baca M, Baptista MA, Brodbeck J, Chan BK, Fiske BK, Honigberg L, Jubb AM, and Katavolos P, et al. (2015) Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Sci Transl Med 7:273ra15.
13. Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, Kaganovich A, van der Brug MP, Beilina A, Blackinton J, and Thomas KJ, et al. (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 23: 329-341.
14. Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, and Goldwurm S, et al.; International LRRK2 Consortium (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 7:583-590.
15. Henderson JL, Kormos BL, Hayward MM, Coffman KJ, Jasti J, Kurumbail RG, Wager TT, Verhoest PR, Noell GS, and Chen Y, et al. (2015) Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl] benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. J Med Chem 58:419-432.
16. Herzig MC, Kolly C, Persohn E, Theil D, Schweizer T, Hafner T, Stemmelen C, Troxler TJ, Schmid P, and Danner S, et al. (2011) LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum Mol Genet 20:4209-4223.
17. Kachergus J, Mata IF, Hulihan M, Taylor JP, Lincoln S, Aasly J, Gibson JM, Ross OA, Lynch T, and Wiley J, et al. (2005) Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 76:672-680.
18. Lee BD, Shin JH, VanKampen J, Petrucelli L, West AB, Ko HS, Lee YI, Maguire-Zeiss KA, Bowers WJ, and Federoff HJ, et al. (2010) Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med 16: 998-1000.
19. Mortiboys H, Johansen KK, Aasly JO, and Bandmann O (2010) Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology 75:2017-2020.
20. Nguyen HN, Byers B, Cord B, Shcheglovitov A, Byrne J, Gujar P, Kee K, Schüle B, Dolmetsch RE, and Langston W, et al. (2011) LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 8: 267-280.
21. Paisán-Ruíz C, Jain S, Evans EW, Gilks WP, Simón J, van der Brug M, López de Munain A, Aparicio S, Gil AM, and Khan N, et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44: 595-600.
22. Ramsden N, Perrin J, Ren Z, Lee BD, Zinn N, Dawson VL, Tam D, Bova M, Lang M, and Drewes G, et al. (2011) Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. ACS Chem Biol 6:1021-1028.
23. Reinhardt P, Schmid B, Burbulla LF, Schöndorf DC, Wagner L, Glatza M, Höing S, Hargus G, Heck SA, and Dhingra A, et al. (2013) Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERKdependent changes in gene expression. Cell Stem Cell 12:354-367.
24. Reith AD, Bamborough P, Jandu K, Andreotti D, Mensah L, Dossang P, Choi HG, Deng X, Zhang J, and Alessi DR, et al. (2012) GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. Bioorg Med Chem Lett 22:5625-5629.
25. Saha S, Guillily MD, Ferree A, Lanceta J, Chan D, Ghosh J, Hsu CH, Segal L, Raghavan K, and Matsumoto K, et al. (2009) LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J Neurosci 29: 9210-9218.
26. Sanders LH, Laganière J, Cooper O, Mak SK, Vu BJ, Huang YA, Paschon DE, Vangipuram M, Sundararajan R, and Urnov FD, et al. (2014) LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction. Neurobiol Dis 62: 381-386.
27. Sheng Z, Zhang S, Bustos D, Kleinheinz T, Le Pichon CE, Dominguez SL, Solanoy HO, Drummond J, Zhang X, and Ding X, et al. (2012) Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sci Transl Med 4:164ra161.
28. Tong Y, Giaime E, Yamaguchi H, Ichimura T, Liu Y, Si H, Cai H, Bonventre JV, and Shen J (2012) Loss of leucine-rich repeat kinase 2 causes age-dependent biphasic alterations of the autophagy pathway. Mol Neurodegener 7:2.
29. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, and Dawson TM (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 102: 16842-16847.
30. Yue M, Hinkle KM, Davies P, Trushina E, Fiesel FC, Christenson TA, Schroeder AS, Zhang L, Bowles E, and Behrouz B, et al. (2015) Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. Neurobiol Dis 78:172-195.
31. Zhang J, Deng X, Choi HG, Alessi DR, and Gray NS (2012) Characterization of TAE684 as a potent LRRK2 kinase inhibitor. Bioorg Med Chem Lett 22:1864-1869.
32. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, and Calne DB, et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44: 601-607.